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Abstract
Purpose: Noninvasive prenatal testing (NIPT) has changed the landscape of prenatal
genetic evaluation. This novel test can be performed as early as 10 weeks gestation
without risk of pregnancy complication and has evoked questions about its applicability,
appropriate use, and patient response. The purpose of this study was to evaluate patient
decision-making processes about prenatal testing options as NIPT is integrated into the
clinical realm. Method: Prenatal patients who were offered NIPT during genetic
counseling (N = 105) in three cities in South Carolina completed a survey to address the
goals of this study. Results: The top five factors most frequently rated as important by
participants were as follows: (1) To be prepared if the baby had a disability (91%), (2)
To avoid the risk of miscarriage (88%), (3) For reassurance the baby does not have a
genetic condition (86%), (4) To obtain genetic information about the fetus as early as
possible (81%), and (5) To have a test that provides more accurate information than other
tests (77%). Three factors were found to be significantly more important to participants
who selected NIPT than to participants who did not: (1) To obtain genetic information
about the fetus as early as possible (p = .021), (2) To have a test that provides more
accurate information than other tests (p = .025), and (3) To be prepared if the baby had a
disability (p = .001). In addition, a majority of participants (74%) felt consideration of
termination if the baby had a chromosome condition was irrelevant to their decision.
This factor was not an NIPT-selection factor, meaning participants who selected NIPT
were not significantly more
iv

likely to consider termination of an affected pregnancy important to their decision than
participants who did not select NIPT. Conclusions: Patients are faced with new
decisions as NIPT is integrated into prenatal care. This study evaluated the top five
factors most frequently rated important by participants about their prenatal testing
decision and identified three NIPT-selection factors. While every patient should be
counseled as a unique individual, the results from this study are observations that may
help healthcare providers better understand patient perspective. This study reveals five
factors important to patient decision-making regarding prenatal testing; of these, three
factors (obtaining genetic information about the fetus as early as possible, having a test
that provides more accurate information than other tests, and being prepared if the baby
had a disability) were significantly influential in patient selection of NIPT.
Keywords: Noninvasive prenatal testing (NIPT), patient decision making,
decision-making process, prenatal genetic testing
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Chapter 1: Background
Since 2011, noninvasive prenatal testing (NIPT) has been clinically available to obtain
near-diagnostic results for aneuploidy as early as 10 weeks gestation without risk of
pregnancy complication (Wilson et al., 2012). As this novel test integrates into the
prenatal clinic, questions have been raised about its applicability, appropriate use, and
how patients will respond. To address these questions, it is important to consult accepted
practice guidelines, research, and ethical statements.

An understanding of available

prenatal testing and screening options is necessary to appreciate the conflict surrounding
the role of NIPT in conjunction with or as a replacement for established prenatal tests.
The following literature review attempts to provide an overview of prenatal testing and
screening options currently available, the ethical implications of adding NIPT to these
options as well as explore how patients make decisions about prenatal testing, and
anticipatory patient response to NIPT.
1.1 Prenatal Diagnostic Testing
Prenatal diagnosis is typically offered by healthcare practitioners to patients
whose pregnancies are at increased risk for chromosomal abnormalities or genetic
disorders. Indications for diagnostic testing include: a woman age 35 or older at delivery,
an abnormal result on a screening test, a family history of a hereditary condition, or fetal
anomalies seen on ultrasound. While these indications prompt healthcare providers to
discuss testing options with patients, diagnostic testing and ultrasound are available to all
pregnant women (ACOG, 2007a).

Current diagnostic procedures, such as
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amniocentesis and chorionic villus sampling (CVS), use invasive methods to determine
whether a fetus is affected with a genetic condition and provide highly sensitive results.
Chorionic villus sampling is used to detect chromosomal aneuploidy in the first
trimester between weeks 10 and 13.

Ultrasound guidance is required to remove

trophoblastic tissue from the placenta with a catheter, either transcervically or
transabdominally. CVS results are obtained with 98%-99% accuracy, with a <1% chance
of mosaicism and a <1% chance for maternal cell contamination.

Mosaicism in CVS

cytogenetic analysis is often confined to the placenta, and amniocentesis is recommended
for confirmation of the fetal karyotype (Collins & Impey, 2012). The CVS procedurerelated chance of miscarriage approximates 0.5%-1% for both singleton and twin
pregnancies (Wilson et al., 2012). Other complications after CVS can involve vaginal
spotting or bleeding, which may occur in up to 32.2% of transcervical procedures, and
less often in a transabdominal approach. The incidence of culture failure or amniotic
fluid leakage after CVS is less than 0.5% (Milunsky, 2004). CVS procedures performed
before 10 weeks have been shown to increase the risk of fetal limb defects (World Health
Organization, 1992).
Amniocentesis is used to detect chromosomal aneuploidy in the second and third
trimesters, starting at 15 weeks gestation. Ultrasound guidance is required to insert a
needle transabdominally into the amniotic sac to withdraw 20-30 cc of amniotic fluid,
which contains fetal cells.
accuracy.

Amniocentesis results are obtained with 99.7%-99.9%

The procedure-related chance of miscarriage approximates 1/300-1/500

(ACOG, 2007b). Potential complications include a 1%-2% chance of vaginal spotting or
amniotic fluid leakage and <0.1% chance of chorioamnionitis (Borgida, Mills, Feldman,
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Rodis, & Egan, 2000). Needle injuries to the fetus are very rare but have been reported.
Amniotic fluid cell culture failure occurs in 0.1% of samples (ACOG, 2007b).
While CVS and amniocentesis are most often used for chromosomal analysis by
karyotyping, they can serve other functions. CVS may be used to test for biochemical
abnormalities, single gene conditions, and collagen abnormalities, but cannot test for
open neural tube defects (ONTDs). Amniocentesis can test for ONTDs, biochemical
abnormalities, and single gene conditions (Wilson et al., 2012).
1.2 Prenatal Screening Procedures
Prenatal screening for aneuploidy is a standard of healthcare offered to all
pregnant women. Screening procedures allow high-risk pregnancies to be identified;
women with these pregnancies are then offered diagnostic testing. Two of the most
common prenatal screening techniques are first trimester screening (FTS) and second
trimester multiple marker screening (MMS). Screening tools are meant to be highly
accessible and do not present risk to the pregnancy. Most laboratories target a 5% false
positive rate for serum screening options (ACOG, 2007a).
First trimester screening identifies trisomy 21 with a sensitivity of 90% and
trisomies 18 and 13 with a sensitivity of 95% (ACOG, 2007a). Nuchal translucency (NT)
measurements are combined with maternal age and the levels of two proteins, human
chorionic gonadotropin (hCG) and pregnancy plasma associated protein A (PAPP-A), to
estimate the chance for aneuploidy unique to a pregnancy. PAPP-A and hCG are
measured between 9w0d-13w6d, while the nuchal translucency (NT) measurement must
be taken between 10w4d-13w6d. The patterns of the levels of the serum analytes change
the chance for aneuploidy. For example, relative low hCG and low PAPP-A levels
increases the chance for trisomy 18 or 13. Likewise relative increased hCG and low
3

PAPP-A increases the chance for trisomy 21 (Shamshirsaz, Benn, & Egan, 2010). A
significantly elevated NT measurement (>3.0mm or the 95th percentile) is correlated with
an increased chance of chromosomal aneuploidy, and it is appropriate to offer diagnostic
testing whether the patient has a positive screening result or not.

Elevated NT

measurements above 3.5mm are associated with an increased chance of congenital heart
defects; thus a fetal echocardiogram is appropriate. A late development or lack of a
lymphatic system could also cause an elevated NT measurement. Even if a normal fetal
karyotype is confirmed, the chance for an adverse pregnancy outcome remains elevated
(ACOG, 2007a).
One recent study summarizing the results of first trimester screening performed at
a single clinical center over a 10-year period found first trimester screening to be
efficacious in identifying pregnancies with trisomies 13, 18, and 21. However, 29% of
chromosomally abnormal fetuses identified to be at risk for these aneuploidies actually
had a different chromosome complement. The authors suggest that prior to invasive
diagnostic testing following a positive serum screen, patients should be counseled about
the possible presence of a fetal aneuploidy other than trisomies 13, 18, and 21 (Alamillo,
Krantz, Evans, Fiddler, & Pergament, 2013).
First trimester screening does not assess risk for ONTDs. Thus, a maternal serum
alpha-fetoprotein (MSAFP) screen should be offered in the second trimester to patients
who choose to undergo FTS (ACOG, 2007a).
There are three options for first trimester screening: (1) NT only with maternal
age uses only the fetal NT measurement and maternal age, (2) First trimester analyte
screening uses the levels of the analytes combined with maternal age, and (3) Combined
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first trimester screening uses the NT measurement, the serum analytes, and maternal age.
The last approach has been shown to have the highest detection rates (ACOG, 2007a).
Multiple marker screening is offered between weeks 15w0d-21w6d of gestation.
This test assesses risk of trisomies 18 and 21 (not 13) and ONTDs by considering
maternal age, weight, race, diabetic status, and protein analytes produced by pregnancy
and found in the maternal bloodstream. Options include the “triple” screen and the
“quad” screen. The triple screen measures the levels of maternal serum alpha-fetoprotein
(AFP), hCG, and unconjugated estriol (uE3). The quad screen adds dimeric inhibin-A
(DIA), which increases the detection rate for Down syndrome. The quad screen has a
higher detection rate, with a sensitivity for Down syndrome of 75%-83% and a sensitivity
for trisomy 18 of 60%-70% (ACOG, 2007a).
Similar to FTS, MMS identifies patterns that indicate an increased chance for
trisomies 18 or 21. For example: elevated hCG and DIA in association with low AFP
and uE3 indicate increased risk for trisomy 21; and low AFP, hCG, and uE3 levels
indicate increased risk for trisomy 18. In addition, high levels of AFP (>2.5MoM) are an
indication for an increased risk for an ONTD (Shamshirsaz et al., 2010).
Typically, patients opt for FTS aneuploidy screening or second trimester MMS,
depending at what gestational age they present for prenatal care; however some practices
utilize a combined approach. There are three options when combining FTS and MMS:
integrated screening, stepwise sequential screening, and contingency screening. Using a
combined approach increases detection rates and decreases false positive rates, but poses
the difficulty of requiring multiple appointments to complete the process. All combined
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screening approaches have similar detection rates. For example, integrated screening
detects Down syndrome at 94%-96% and trisomy 18 at 91%-96% (Wilson et al., 2012).
Integrated screening combines the results from NT and PAPP-A measurements in
the first trimester and serum analytes AFP, hCG, uE3, and DIA in the second trimester.
No results are revealed until after the second step, when they are combined.

Stepwise

sequential screening begins with a first trimester calculation including an NT
measurement, maternal age, and serum analytes PAPP-A and hCG. Results are disclosed
to individuals at high risk for fetal aneuploidy, and these individuals are offered
diagnostic testing. Individuals not in the high-risk group proceed to the second trimester
blood draw, which uses serum analytes AFP, hCG, uE3, and DIA.

Contingency

screening adjusts maternal age-alone chance for aneuploidy based on serum analytes and
fetal NT measurement. Patients are divided into low, medium, and high risk groups
based on their results and are offered no further testing, the second trimester serum
analyte screening step, or diagnostic testing, respectively. The medium risk group are
then further sorted into a high risk group who are offered diagnostic testing and a low risk
group who are not offered further testing by the results of the second screening step
(ACOG, 2007a).
1.3 Noninvasive Prenatal Testing
As early as 1997, Lo et al. recognized that cell-free fetal DNA (cffDNA) accounts
for 5%-10% of total free-floating DNA in the maternal bloodstream and is easier to
isolate from maternal blood than cellular fetal DNA (Lo et al., 1997). This discovery
prompted an effort to discover a reliable method for NIPT for fetal genetic conditions.
Massively parallel sequencing (MPS) and selective analysis of cell-free fetal DNA in
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maternal plasma are two methods that are highly sensitive and specific screening tools for
common fetal chromosome aneuploidies (Wilson et al., 2012).
MPS allows large quantities of cffDNA to be read in a short amount of time with
high through-put sequencing. Maternal and fetal DNA sequences are then assigned to the
chromosome from which they originated and are quantified as a ratio. This results in a
specific amount of genetic material read for a particular chromosome, which can be
compared to the amount of genetic material that is present if the genotype is typical. An
increase in detection of genetic material for chromosome 21, for example, would indicate
trisomy 21 (Lo, 2012).
Massively parallel sequencing has been instrumental in detecting subtle
quantitative differences between affected and unaffected pregnancies.

Consider the

example of detecting a pregnancy affected with trisomy 21: if 5% of cell free DNA in
the maternal bloodstream originates in the fetus, the cffDNA from each copy of
chromosome 21 of an unaffected fetus comprises 2.5% of the total cell free DNA for
chromosome 21 in the maternal bloodstream. A pregnancy affected with trisomy 21
should have 2.5% more fetal chromosome 21 transcripts than an unaffected pregnancy.
Because the mother supplies the majority (95%) of the cell free DNA, detecting a subtle
2.5% overall difference requires advanced technology and laboratory expertise (Simpson,
Richards, Ontano, & Driscoll, 2012).
Identification of trisomies in twin gestations relies on a small incremental increase
in the proportion of DNA fragments. Both monozygotic and dizygotic twin pregnancies
have higher placental mass than singleton pregnancies; thus it is expected they contribute
more fetal DNA to maternal circulation and consequently have higher fetal fraction.
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Canick et al. (2012) found that on average multiple pregnancies contributed 35% more
fetal DNA to the total free DNA in maternal plasma than singleton pregnancies. The
largest study on MPS in twin gestations to date correctly classified seven pregnancies
with trisomy 21, one with trisomy 13, and seventeen euploid pregnancies (two of which
were triplets) with a detection rate of 100% and confidence interval of 95% (Canick et
al., 2012).

However, if NIPT is abnormal, which twin is affected is indiscernible.

Confirmation by amniocentesis of each fetal sac is recommended when fetal trisomy is
detected in twin pregnancies by NIPT (Canick et al., 2012).
Selective analysis sequences cell-free DNA from maternal plasma for selected
loci from specific chromosomes of interest. Selective analysis and MPS both utilize
sequencing technology, but unlike MPS, selective analysis only sequences DNA from
chromosomes of interest and not the entire genome, which increases throughput. A novel
selective analysis assay, digital analysis of selected regions (DANSR), generates
sequencing templates from chromosome-specific assays and produces high mapping rates
(Sparks et al., 2012). Thus, selective analysis has been proposed to be a more efficient
and less expensive option for NIPT. Fetal-fraction optimized risk of trisomy evaluation
(FORTE), a process of using fetal fraction of cffDNA results from sequencing cffDNA
and generating a risk score, has been shown to estimate accurately the risk of aneuploidy
(Sparks et al., 2012).
At least 5% of NIPT samples are yielding noninformative results due to
insufficient cffDNA. Samples can be taken at 10 weeks gestation or any time after, but
cffDNA levels do not increase with advancing gestational age (Simpson, 2013).
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The newest advancements in NIPT focus on attaining diagnostic competency for
aneuploidy detection, but this technology also provides access to RhD genotyping, fetal
sex determination, paternity testing, and limited single gene testing.

Although the

proposed research project focuses on advancements in detecting fetal chromosomal
aneuploidy, it should be recognized that NIPT has been used to fulfill these other
purposes, which will be described briefly. Detection of RhD sequence in the bloodstream
of an RhD-negative mother indicates the fetus is RhD-positive and warrants
administration of Rh immune globulin.

Using the same strategy, if Y-sequence is

detected in the maternal bloodstream, one may deduce that the fetus is generating this
genetic material and thus is a male (Simpson et al., 2012). Paternity is determined using
informative single nucleotide polymorphisms (SNPs) (ie. occurring when the mother and
one potential father are homozygous for the same allele while the other potential father is
homozygous for the alternative allele) (Guo et al., 2012). Certain Mendelian disorders
can be detected from cffDNA if they are paternally derived. For example, polycystic
kidney disease, inherited as an autosomal dominant trait, may be detected in the fetus
noninvasively if the presence of the paternal mutation is found in the blood of the
unaffected mother (Simpson et al., 2012).
NIPT as a prenatal testing option is rapidly evolving yet has limitations.
Conjecture has been put forth that NIPT will eventually reach diagnostic standards
similar to CVS but not amniocentesis. This expectation recognizes that cffDNA are
derived from trophoblasts, the same tissue studied in CVS. Other complications that can
occur with CVS may potentially occur with NIPT as well, such as placental mosaicism.
NIPT will not distinguish between trisomy and unbalanced translocation because the test
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measures the quantity of each chromosome present in the fetus and does not provide a
karyotype image (Benn, Cuckle, & Pergament, 2012). Despite current limitations, the
technology supporting NIPT continues to advance and will likely have a considerable
role in current and future prenatal assessment algorithms.
1.4 Noninvasive Prenatal Testing: Transitioning from Laboratory to Clinical
Practice
The development of NIPT has been funded primarily by the private sector and is
considered a Laboratory Developed Test (LDT). LDTs are developed, evaluated, and
validated within one laboratory; unlike commercial tests, they are not manufactured and
marketed to several labs. Consequently, LDTs are not regulated by the U.S. Food and
Drug Administration. Multiple laboratories have developed processes for NIPT (Orton,
2012).
Three large-scale clinical trials have been published by two separate groups that
used MPS of maternal plasma to detect an overrepresentation of chromosome material.
An international study using MPS released two sets of analyzed data: one on trisomy 21
in 2011 and one on trisomies 18 and 13 in 2012. This multicenter study detected trisomy
21 with a sensitivity and specificity close to 99% (Palomaki et al., 2011). The follow-up
study detected trisomy 18 with a sensitivity of 100% and a specificity of 99.7% and
trisomy 13 with a sensitivity of 91.7% and a specificity of 99.1% (Palomaki et al., 2012).
Another group also used MPS to evaluate high-risk pregnancies for chromosome
conditions. This study detected trisomy 21 with a sensitivity of 100%, trisomy 18 with a
sensitivity of 97.2%, and trisomy 13 with a sensitivity of 78.6%. All three were detected
with a specificity of 100%.

In addition, this study found a 94% detection rate for
10

monosomy X and reported several cases of mosaicism for trisomy 21, trisomy 18 and
monosomy X (Bianchi et al., 2012).
Other studies have validated NIPT through selective analysis. A multicenter
cohort study performed chromosome-selective sequencing on chromosomes 21 and 18 in
a population of women undergoing CVS or amniocentesis for any indication.

The

sensitivity and specificity for trisomy 21 were 100% and 99.97%. The sensitivity and
specificity for trisomy 18 were 97.4% and 99.93% (Norton et al., 2012). Another study
reported 80% sensitivity and 99.95% specificity for trisomy 13 (Ashoor, Syngelaki,
Poon, Rezende, & Nicolaides, 2013).
NIPT first became clinically available in October of 2011 when Sequenom
released MaterniT21™, a test for Down syndrome that uses MPS to detect cffDNA
(Sequenom CMM, 2011). Sequenom has since included detection for chromosomes 13,
18, and Y in the more recent version of its test, MaterniT21Plus™ (Palomaki et al.,
2011). In 2012, Sequenom provided evidence that MPS could reliably detect Down
syndrome in women with high-risk twin gestations and added this testing option (Canick
et al., 2012). In February, 2013, Sequenom’s MaterniT21Plus™ included detection for
sex chromosomal aneuploidies (PR Newswire, 2013).
LabCorp (Ariosa Diagnostics) and Verinata Health released similar tests in 2012,
Harmony™ and verify™, respectively. Harmony™ uses MPS to detect cffDNA for
chromosomes 21, 18, and 13. Verifi™ uses MPS to detect chromosomes 21, 18, 13, X,
and Y; thus sex chromosomal aneuploidies such as monosomy X, XXX, XXY, and XYY
are reported (PR Newswire, 2012a; PR Newswire 2012b). Natera is undergoing a clinical
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trial, PreNATUS, and once clinically validated will offer testing for trisomies 21, 13, and
18 and sex chromosomal aneuploidies (Biotechnology Industry Organization, 2012).
The clinical function of NIPT has been debated. The high sensitivity of the test
has called to question whether it may be used for diagnostic purposes. In fact, NIPT is
also known in current literature as noninvasive prenatal diagnosis (NIPD). However,
guidelines and statements issued by professional organizations agree that NIPT should be
considered a screening tool at this point in time, and only offered to high risk
populations. A 2012 position statement by the National Society of Genetic Counselors
(NSGC) stated that currently it “is recommended only as a highly specific screening
measure for high-risk pregnancies, which requires follow-up diagnostic testing” (Devers
et al., 2013). The International Society for Prenatal Diagnosis (ISPD) made a similar
statement, which follows: “[T]his test is not fully diagnostic and therefore constitutes an
advanced screening test. Accordingly, confirmation of MPS positive results through
invasive testing would still be required” (Benn et al., 2011b, p.1). The American College
of Obstetricians and Gynecologists (2012) reaffirmed this position in their committee
opinion, stating, “A patient with a positive test result should be referred for genetic
counseling and should be offered invasive prenatal diagnosis for confirmation of test
results” (ACOG, 2012, p.1).
The NIPT clinical validation studies recruited only women who were otherwise
pursuing invasive testing; thus the majority of pregnancies were high-risk for aneuploidy.
Consequently, testing is currently offered to high-risk populations only.

Current

indications for NIPT include: advanced maternal age, an abnormal maternal serum
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screen, personal or family history of aneuploidy, or an abnormal ultrasound (Wilson et
al., 2012).
Clinical validation studies of the general population (i.e., low-risk patients) are in
process.

Preliminary evidence indicates NIPT should have similar sensitivity and

specificity in a low-risk population (Nicolaides, Syngelaki, Ashoor, Birdir, & Touzet,
2012). Indeed, research has suggested that NIPT may be an effective screening method
as a standard test for risk assessment of fetal trisomies 21, 18, and 13 in the general
population (Fairbrother, Johnson, Musci, & Song, 2013). With further support, this
advanced prenatal test may be offered to women with low-risk pregnancies (Norton et al.,
2012).
1.5 Patients’ Decision-making in Prenatal Testing
The number of prenatal testing options available to prospective parents has
significantly increased during the past half-century. This presents prenatal patients with
what can feel like a menu of confusing choices. The methods used to navigate these
choices and reasons for making decisions are unique to each woman, and healthcare
providers should be aware of the surrounding complexities in order to provide standard
care (Pergament & Pergament, 2012).
Screening options are noninvasive, which make them attractive for patients who
desire individualized risk assessment information about their pregnancy but do not want
an associated risk of miscarriage, or for those who would like to use screening results to
make a decision about whether or not to undergo more comprehensive diagnostic testing.
The primary limitation of screening is that it does not provide a definitive diagnosis,
potentially creating anxiety in women with unaffected pregnancies and falsely reassuring
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women with affected pregnancies (ACOG, 2007b). Diagnostic tests offer a definitive
result, but are associated with a risk of miscarriage (Collins & Impey, 2012).
Many women find NIPT appealing because it gains near-diagnostic genetic
information about the fetus without an associated chance of miscarriage. In fact, when
assessing pregnant women’s level of future interest in NIPT, one study found pregnant
women thought the most important feature of NIPT would be the safety of the fetus
(75%), followed by accuracy (13%), and early availability of results (7%) (Tischler,
Hudgins, Blumenfeld, Greely, & Ormond, 2011).
Reproductive decisions must be understood within the cultural context of the time
period, as genetic testing is constantly evolving. Today in the United States, a strong
emphasis is placed on personal choice, and individuals have unlimited access to
information and external influences, such as the media, the internet, and social media
(Pergament & Pergament, 2012). The uptake of prenatal testing has increased, which
reflects the growing need in couples to seek further information genetic about their fetus
(Pivetti, Montali, & Simonetti, 2012). Prospective parents have higher expectations than
in the past of a successful reproductive outcome (Choolani & Biswas, 2012). This
expectation could potentially stimulate a desire for reassurance about the pregnancy
through prenatal testing.
There are a multitude of personal and social factors that directly and indirectly
affect women’s prenatal testing decisions.

In general, it is accepted that “decision-

making by prospective parents is based on rational assessment of risk, benefit, and
choices, specifically: (1) the risk of a fetal abnormality compared with the loss of a
normal pregnancy after invasive testing; (2) the benefit of gaining reassurance of a
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healthy fetus; and (3) the options available if the fetus is identified as affected by a
genetic, developmental disorder, or both” (Pergament & Pergament, 2012, p. 518).
While these are useful guidelines, understanding specifically what is important to a
patient has important implications in the delivery of service.
Factors that influence women’s reproductive decisions following genetic
counseling may include, for example: perceived pain of diagnostic testing, perceived risk
of diagnostic testing, anxiety of health about the fetus, emotional and social burden of
possible pregnancy termination, financial and social burden of a child with disabilities,
access to prenatal services, past pregnancy history, socioeconomic status, personal
philosophy, social and partner support, healthcare education and support, media, and
uncertainty of genetic tests. Of course, the importance of each factor, how it interacts
with other factors, and the influence it might have over a particular woman’s decision
varies. It is difficult to measure objectively the role each factor plays in a decision
(Pergament & Pergament, 2012).
The overall most frequently reported sources of difficulty for decision-making in
women in a systematic review of 32 unique studies regarding perceptions of Down
syndrome prenatal testing were pressure from others, emotions, and lack of information.
The same study found the most important sources of reassurance for women to be
personal values, understanding, and confidence in the medical system (St-Jacques et al.,
2008).
Prenatal patients often feel ambivalence towards screening and diagnosis of
aneuploidy (Vassy, 2005). It has been postulated that for many women the miscarriage
risk associated with invasive testing is a psychological barrier to diagnostic testing and
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that if this risk were removed, women may feel more inclined to have a diagnostic test
(Newson, 2008). Noninvasive prenatal testing may present an option for near-diagnostic
information about fetal aneuploidy without an associated risk of miscarriage for these
women.
However, some women prefer not to have genetic knowledge of their fetus if the
knowledge does not alter their course of action. Because it is not possible to correct a
chromosome condition cytogenetically, many women perceive termination as the only
available option in light of a positive testing result.

A meta-analysis of pregnant

women’s decision making processes with regard to prenatal screening for Down
syndrome showed that some women consider genetic testing to be pointless, since they
would not terminate the pregnancy even if the result were positive (Reid, Sinclair, Barr,
Dobbs, & Crealey, 2009).
Other women consider genetic testing to be empowering, even if they would
choose not to terminate an affected pregnancy. In fact, one study concluded that the
introduction of NIPT is likely to cause a shift in decision-making that may be associated
with an increase in the uptake of prenatal testing but a decrease in the decision to
terminate pregnancies affected with Down syndrome (Verweij, Oepkes, & De Boer,
2013). Another study surveyed parents of children with Down syndrome: 75% were
disinclined to terminate a future affected pregnancy, but only 33% would not have
prenatal testing (Kuppermann et al., 2011). Learning of a fetus’ diagnosis may provide
the patient time to share the diagnosis with a support network and prepare emotionally.
Studies have been performed to evaluate uptake of invasive diagnostic testing
following unexpected results. Women are more likely to undergo invasive diagnostic
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testing when fetal anomalies are detected on ultrasound or a screening test result is
positive, due to the increased chance for chromosomal aneuploidy (Pryde, Drugan,
Johnson, Isada, & Evans, 1993). A more recent study evaluating factors determining
uptake of invasive testing following first-trimester combined testing found that women
opting for invasive testing are significantly younger and less likely to have had IVF/ICSI.
Women less than 36 years old opt for invasive testing more frequently, regardless of their
chance for Down syndrome, while women 36 years or older are more likely to let the
magnitude of the chance estimate guide their decision (Lichtenbelt et al., 2013).
Research examining psychosocial determinants that influence women’s intention
to undergo prenatal genetic testing found women are more inclined to feel favorably
about prenatal genetic testing if they: (1) are in favor of science and scientific
progression, (2) possess a good knowledge of genetic testing, and (3) can count on the
support of family members and friends. Women’s attitudes about pregnancy termination
are the most predictive indicators of intent to undergo prenatal testing (Pivetti et al.,
2012).
Experience in previous pregnancies has been shown to play a role in women’s
prenatal testing decisions.

Research demonstrates that women who had a previous

miscarriage or termination are more likely to undergo testing than women who have
already given birth to three or more children (Halliday, Lumley, & Watson, 1995).
Research has indicated that women’s perceptions of chance of miscarriage or of
having an affected fetus may form independent of empirical risk estimates. For example,
women aged 35 years and older have a higher perceived chance of Down syndrome than
younger women (this chance is higher in women 35 and over) but a lower perceived
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chance of a procedure-related miscarriage (this chance is the same for both parties).
Other correlations were made between race, socioeconomic status, education level, and
perception of health. Interestingly, women who undergo diagnostic testing perceive a
higher chance of having a baby with Down syndrome and a lower chance of a procedurerelated miscarriage than women who choose not to have a diagnostic procedure
(Caughey, Washington, & Kuppermann, 2008).
Some women are apprehensive about expected pain related to a procedure
(Mujezinovic & Alfirevic, 2011). Research from Turkey reported that actual pain after
amniocentesis was significantly lower compared with perceived pain before the
procedure and anxiety before amniocentesis was significantly higher than anxiety after
the procedure. Of particular interest, women who were informed about the procedure
beforehand perceived the procedure to be less painful and expressed less anxiety before
and after amniocentesis. The authors suggested that pre-amniocentesis counseling should
emphasize that the actual pain and anxiety experienced during amniocentesis are often
significantly lower than expected (Al, Yalvac, Altar, & Dolen, 2009).
Patients’ own demographic characteristics play roles in their prenatal testing
decision making. A meta-analysis of three national polls over a 14-year period, from
1990 to 2004 found married/separated/widowed individuals and those who attended
church on a regular basis were less likely to want prenatal testing than individuals who
were single and/or attended church less often. Catholics were significantly less likely,
and Jewish individuals significantly more likely to opt for prenatal genetic testing
(Singer, Couper, Raghunathan, Van Hoewyk, & Antonucci, 2008).

Another study

documented ethnic differences in the decision to undergo or not undergo prenatal
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screening for aneuploidy, with women from minority groups and of non-Western ethnic
origin less likely to participate (Fransen et al., 2010).
The attitudes of health professionals have been shown to impact the uptake of
Down syndrome screening. In fact, in a study assessing pregnant women’s interest in
NIPT, one in five women said that they would do what their health professional
recommended (Tischler et al., 2011).
Trends have been observed in differences between what women and healthcare
providers consider most important when making a decision about prenatal testing.
Choolani & Biswas (2012) point out that when it comes to risk and benefit of prenatal
testing, what healthcare professionals feel is important, what patients feel is important,
and what healthcare professionals believe patients feel to be important are often three
completely separate things.

Health professionals tend to place a higher value on tests

that are conducted earlier in pregnancy than women, who prefer to wait for a result until
later in pregnancy if the test is safer and more accurate. This discrepancy potentially
could result in screening policies that overemphasize timing in the selection of a test to
the relative neglect of tests associated with lower miscarriage rates and higher detection
rates but conducted later in pregnancy (Bishop et al., 2004).
In another study, both women and health professionals preferred a test with
greater accuracy, no risk of miscarriage, and one that provided as much information as
possible.

However, opinions between the two groups had statistically significant

differences in the coefficients for accuracy, timing, and no risk of miscarriage. Women
strongly preferred a test with no risk of miscarriage: they were prepared to wait more
than twice as long and accept 12% lower accuracy for a test that had no risk of
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miscarriage as compared with health professionals. In contrast, health professionals
preferred to offer a more accurate test, even if it was associated with a small risk of
miscarriage (Hill, Fisher, Chitty, & Morris, 2012).
Further subgroup comparisons in this discrete choice experiment indicated that
women aged 35 years or more placed a greater emphasis on accuracy than younger
women. Women who had undergone Down syndrome screening in their current
pregnancy differed from those who had declined Down syndrome screening in the
emphasis they placed on test timing and information. Of the 50 women who chose not to
have screening for Down syndrome, only 12 indicated that they would not have any test
presented to them on the questionnaire. The authors suggested many of the women who
declined screening for Down syndrome may choose to undergo testing if there is no risk
of miscarriage associated with the definitive diagnosis (Hill et al., 2012).
1.6 Clinical and Ethical Implications of Noninvasive Prenatal Testing
The extraordinary momentum with which the technology of NIPT has forged
ahead is impressive. However, many feel hesitant to offer NIPT in a clinical setting
without further consideration of ethical repercussions. It is the responsibility of those
who provide and regulate healthcare to reflect on the benefits and risks of particular tests
so that these are explained to patients, guidelines are established, and advancements in
NIPT progress in a responsible manner.
NIPT presents many advantages to women. It is a noninvasive test without
association of miscarriage that supplies highly sensitive results and imposes less time
restrictions on gestational age than other prenatal tests.

Eliminating the risk of

miscarriage associated with invasive testing means women do not have to factor this
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anxiety-producing prospect into their decision. Early detection of unaffected pregnancies
could allow for parental reassurance and for bonding to occur sooner (Newson, 2008).
Women with affected pregnancies have advantages in their options as well. Parents may
use this time to prepare emotionally, make an appropriate delivery plan, and assemble a
medical management team. If parents decide to terminate an affected pregnancy, this
may be physically safer and psychologically less traumatic at an earlier gestational age
(Benn & Chapman, 2010).
For some, the fact that a termination can occur early in gestation may make a
morally relevant difference. De Jong et al. (2010) point out that the dominant opinion in
most western countries, also reflected in legislation, is that the moral status of the fetus
progressively increases with its development (De Jong, Dondorp, De Die-Smulders,
Frints, & De Wert, 2010). Current guidelines recommend abnormal NIPT results be
confirmed by CVS or amniocentesis prior to termination, so there may be additional
delay after the results of the NIPT are received before the diagnosis is confirmed. This
could present a stressful period of waiting. (Benn et al., 2012).
Some have expressed concern about potential negative repercussions of NIPT
because there is no increased risk for miscarriage.

The uptake of NIPT has been

projected to increase detection of affected pregnancies and may in turn lead to an
increased number of terminations (Newson, 2008).

When understood from this

perspective, the ease with which this test is undertaken and the fact that results are
received early in pregnancy are seen by some as threatening conveniences that may
promote termination of affected pregnancies. It has been suggested that receiving results
of an affected fetus at an early gestational age, perhaps before parents have bonded with
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the fetus or shared publicly the pregnancy encourages termination without thoughtful
reflection (Skotko, 2009).
This concern has been further projected: NIPT may lead to fewer individuals with
disabilities to be born, which may lead to reduced social acceptance and financial support
for those who live with disabilities (Skotko, 2009). Some disability advocates contend
that the implicit aim of prenatal genetic testing is to prevent the birth of disabled babies,
which demeans and undermines the worth of individuals living with disabilities (Benn &
Chapman, 2010). If this apprehension becomes reality, it has been suggested that societal
pressures regarding individuals with disabilities may cause women to feel undue pressure
to undergo NIPT and terminate an affected pregnancy (Tischler et al., 2011).
Advocates of the disability community are not alone in their concern about the
potential negative effects of NIPT on the reproductive trends of the population. Many
worry there could be unintended consequences. One such concern is that the risk-free
and simple process of NIPT will lead to the routinization of the test. In other words,
NIPT may become a standard test that most women uptake simply because other women
uptake and thus it seems “normal”. While this might increase efficiency and improve
uptake, routinization could potentially undermine the decision-making process (Deans &
Newson, 2011). Others feel alarmed by the reproductive power NIPT offers and wonder
if in the future, a fetus might have to meet certain standards of desirable traits to qualify
for birth. One ethicist suggested that potentially “every pregnancy becomes a ‘tentative
pregnancy’ pending the results of prenatal screening” (Benn & Chapman, 2010, p. 131).
A primary cause for unease in this ethical quandary revolves around the concern
that patients may not be afforded equal quality of pretest counseling as they would with
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an amniocentesis or CVS. Obviously, women do not need to be counseled about risk of
miscarriage associated with NIPT.

To some extent, this lessens the gravity of the

decision of prenatal testing, and indicates a difference in counseling between NIPT and
invasive testing. However, the definitive nature of the information received and the
significance of the decisions that might be made from this information necessitates
pretest genetic counseling (Deans & Newson, 2011).
Because pretest informed consent is imperative for NIPT, there is an increased
need for genetic counseling ( Benn, Cuckle, & Pergament, 2012). The genetic counselor
and the obstetrician serve to provide accurate and objective information about the
implications, advantages, disadvantages, and consequences of any genetic testing
(Pergament & Pergament, 2012). Patients have indicated mixed interest in pretest NIPT
counseling but seem eager to meet with a genetic counselor to discuss results. A 2011
study assessing women’s potential interests in NIPT demonstrated 50% of respondents
indicated they would like pretest genetic counseling and 94.6% were interested in
discussing test results with a genetic counselor (Tischler et al., 2011).
NIPT has invoked a variety of attitudes and opinions in healthcare and among the
public about how most responsibly and ethically to implement this new option. Among
attendees at a continuing medical education course on obstetrics and gynecology in 2011,
enthusiasm, caution, discomfort, and uncertainty were among the feelings that
surrounded the test. Genetic counseling and professional society approval were rated
important to the implementation of NIPT. Respondents indicated a higher comfort level
with the idea of offering testing for chromosomal abnormalities or single-gene disorders
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than for sex determination or late-onset conditions (Sayres, Allyse, Norton, & Cho,
2011).
A similar study assayed public opinion on NIPT.
respondents relayed a positive first impression of NIPT.

The majority (63%) of
Yet many expressed

ambivalence, affirming the individual/medical rationale for NIPT but expressing unease
concerning the public health rationale and societal implications. Subjects of concern
included eugenic reasoning, too much reproductive control, commercial provision,
information and support requirements for expanded testing, and limiting the use of
testing. These results suggest that public preference is to regulate commercial provision
of NIPT services and to monitor its introduction and clinical use (Kelly, 2012).
Noninvasive prenatal testing presents patients, genetic counselors, and physicians
with exciting opportunities to gain accurate knowledge of a fetus early in gestation
without increasing the risk of miscarriage. As this technology is integrated into prenatal
practice, quality informed consent is imperative as well as thoughtful consideration of
how best ethically and responsibly to employ NIPT. Despite the conflict surrounding
NIPT, its presence in the prenatal setting is powerful and undeniable; it has major
implications on reproductive health important to all (Tischler et al., 2011). It is essential
that healthcare providers appreciate how NIPT changes the realm of prenatal testing from
the perspective of a patient and complicates the decision-making process.
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Chapter 2: Manuscript
Prenatal Decision-making Process of Patients in Three Cities in South Carolina 1
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Hamann, K.H., Edwards, J.E., Shulman, L.P., & Gordon, B. To be submitted to Journal of Genetic
Counseling
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2.1 Abstract
Purpose: Noninvasive prenatal testing (NIPT) has changed the landscape of prenatal
testing. This novel test, which can be performed as early as 10 weeks gestation without
risk of pregnancy complication, has evoked questions about its applicability, appropriate
use, and patient response. The purpose of this study was to evaluate patient decisionmaking processes about prenatal testing options as NIPT is integrated into the clinical
realm. Method: Prenatal patients who were offered NIPT during genetic counseling (N =
105) in three cities in South Carolina completed a survey to address the goals of this
study. Results: The top five factors most frequently rated as important to their decisionmaking about prenatal testing by participants were as follows: (1) To be prepared if the
baby had a disability (91%), (2) To avoid the risk of miscarriage (88%), (3) For
reassurance the baby does not have a genetic condition (86%), (4) To obtain genetic
information about the fetus as early as possible (81%), and (5) To have a test that
provides more accurate information than other tests (77%). Three factors were found to
be significantly more important to participants who selected NIPT than to participants
who did not: (1) To obtain genetic information about the fetus as early as possible (p =
.021), (2) To have a test that provides more accurate information than other tests (p =
.025), and (3) To be prepared if the baby had a disability (p = .001). In addition, a
majority of participants (74%) felt consideration of termination if the baby had a
chromosome condition was irrelevant to their decision. This factor was not an NIPTselection factor, meaning participants who selected NIPT were not significantly more
likely to find this factor important to their decision than participants who did not select
NIPT. Conclusions: Patients are faced with new decisions as NIPT is integrated into
prenatal testing options. This study evaluated the top five factors most frequently rated
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as important by participants about their prenatal testing decision and identified three
NIPT-selection factors. While every patient should be counseled as a unique individual,
the results from this study are observations that may help healthcare providers better
understand patient perspective This study reveals five factors important to patient
decision-making regarding prenatal testing; of these, three factors (obtaining genetic
information about the fetus as early as possible, having a test that provides more accurate
information than other tests, and being prepared if the baby had a disability) were
significantly influential in patient selection of NIPT.
Keywords: Noninvasive prenatal testing (NIPT), patient decision making,
decision-making process, prenatal genetic testing
2.2 Introduction
Since 2011, noninvasive prenatal testing (NIPT) has been clinically available to
obtain near-diagnostic results for aneuploidy as early as 10 weeks gestation without risk
of pregnancy complication (Wilson et al., 2012). As this novel test integrates into the
prenatal clinic, questions have been raised about its applicability, appropriate use, and
how patients will respond.
Prenatal testing has traditionally been divided into screening and diagnostic tests.
Prenatal screening for aneuploidy is a standard of healthcare offered to all pregnant
women. Screening procedures allow high-risk pregnancies to be identified; women with
these pregnancies are then offered diagnostic testing. Screening tools are meant to be
highly accessible and do not present risk to the pregnancy (ACOG, 2007a). Conversely,
prenatal diagnosis is typically offered by healthcare practitioners to patients whose
pregnancies are at increased risk for chromosomal abnormalities or genetic disorders.
These invasive methods provide sensitive results about genetic conditions but are
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associated with procedure-related complications, such as a risk of miscarriage (Collins &
Impey, 2012).
Noninvasive prenatal testing uses cell-free fetal DNA (cffDNA) from the
maternal bloodstream to achieve near-diagnostic results for aneuploidy without an
associated risk of miscarriage. Noninvasive prenatal testing is currently not available to
all patient populations.

The NIPT clinical validation studies recruited only women

otherwise pursuing invasive testing; thus the majority of pregnancies were high-risk for
aneuploidy. Consequently, testing is currently offered to high-risk populations only.
Current indications for NIPT include: advanced maternal age, an abnormal maternal
serum screen, personal or family history of aneuploidy, or an abnormal ultrasound
(Wilson et al., 2012). Clinical validation studies of the general population (i.e., low-risk
patients) are in process and may become a reality in the near future

(Nicolaides,

Syngelaki, Ashoor, Birdir, & Touzet, 2012; Fairbrother, Johnson, Musci, & Song, 2013;
Norton et al., 2012).
Prenatal patients often feel ambivalence towards screening and diagnosis of
aneuploidy (Vassy, 2005). The primary limitation of screening is that it does not provide
a definitive diagnosis, potentially creating anxiety in women with unaffected pregnancies
and falsely reassuring some women with affected pregnancies (ACOG, 2007b).
Diagnostic tests offer a definitive result, but are associated with a risk of miscarriage
(Collins & Impey, 2012). The high sensitivity of NIPT has called to question whether it
may be used for diagnostic purposes. However, guidelines and statements issued by
professional organizations agree that NIPT should be considered a screening tool at this
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point in time, and recommend that positive results be followed up by invasive diagnostic
procedures (ACOG, 2012; Benn et al., 2011a; Devers et al., 2013).
There are a multitude of personal and social factors that directly and indirectly
affect women’s prenatal testing decisions. Many women find NIPT appealing because it
gains near-diagnostic genetic information about the fetus without an associated chance of
miscarriage. In fact, when assessing pregnant women’s level of future interest in NIPT,
one study found pregnant women thought the most important feature of NIPT would be
the safety of the fetus (75%), followed by accuracy (13%), and early availability of
results (7%) (Tischler, Hudgins, Blumenfeld, Greely, & Ormond, 2011).
NIPT presents many advantages to women.

However, some have expressed

concern about potential negative repercussions of NIPT because there is no increased risk
for miscarriage. The uptake of NIPT has been projected to increase detection of affected
pregnancies and may in turn lead to an increased number of terminations (Newson,
2008).

When understood from this perspective, the ease with which this test is

undertaken and the fact that results are received early in pregnancy are seen by some as
threatening conveniences that may promote termination of affected pregnancies (Skotko,
2009).
NIPT presents patients, genetic counselors, and physicians with exciting
opportunities to gain accurate knowledge of a fetus early in gestation without increasing
the risk of miscarriage. As this technology is integrated into prenatal practice, quality
informed consent is imperative as well as thoughtful consideration of how best ethically
and responsibly to employ NIPT. Despite the conflict surrounding NIPT, its presence in
the prenatal setting is powerful and undeniable. It has major implications on reproductive
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health important to all (Tischler et al., 2011). Healthcare providers need to appreciate
how NIPT shifts the realm of prenatal testing and understand how to evaluate opinion of
this change.
2.3 Materials and Methods
2.3.1 Participants. This study surveyed prenatal patients who were offered NIPT
during genetic counseling about the motivations and reasons for their prenatal testing
decision. Regardless of their prenatal testing decision, eligible patients were invited to
participate by genetic counselors after the genetic counseling session ended. Interested
patients were given the option to complete a survey at the prenatal office or to mail a
response in a pre-paid envelope. For every patient who completed a survey, a genetic
counselor completed a data collection form with basic information about the patient’s
indication for genetic counseling, testing offered, and testing decision. The patient
surveys and genetic counselor data collection forms were numbered in sets such that data
collection forms could be matched to respective patient surveys. Thus, patient
confidentiality was maintained. Three South Carolina locations were sampled:
University Specialty Clinics of University of South Carolina School of Medicine in
Columbia, Medical University of South Carolina in Charleston, and the Greenville
Hospital System in Greenville. This study was approved by the Institutional Review
Board at the Medical University of South Carolina in December, 2012.
2.3.2 Research Methods. The patient survey consisted of a series of questions
designed to assess factors most influential to patients in their prenatal testing decision.
The format of the survey was primarily quantitative and utilized both Likert scale and
multiple choice questions with the opportunity to specify other possible responses. The
final question was open-ended and thus qualitative in nature. In total, the survey
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consisted of thirty items. Questions were engineered to assess patient prenatal testing
intentions pre- and post- genetic counseling. Patients were asked to rank the importance
or relevance of specific factors to their decision, such as insurance covering testing or a
recommendation by a physician. Demographic information was collected related to age,
gestational age, annual household income, etc.
The genetic counselor data collection form was engineered to provide objective
and accurate patient information about indication for genetic counseling, gestational age,
testing offered during genetic counseling, and testing currently pursued. This form
consisted of four quantitative questions, mostly multiple choice.
2.3.3. Statistical Analysis. Statistical Package for the Social Sciences (SPSS),
version 21.0, was used to analyze quantitative data.

Ordinal categorical data were

reviewed using frequency, proportions, and percentages. Likert scale questions were
reviewed item by item. In addition, an exploratory factor analysis was performed and
reliability statistics calculated to determine if items were similar enough to create a
“factor”. These items were reviewed as categorical groups. Chi-square tests were used
to compare responses of Likert scale questions. Multiple response questions were coded
individually by response and analyzed using Chi-square test and Fisher’s Exact Test.
Open-ended responses were categorized into thematic groups and sub-groups for
reporting.
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2.4 Results
Data were collected from December, 2012, to March, 2013. A total of 105 patient
surveys accompanied by genetic counselor data collection forms were collected: 51 from
Columbia, SC, 32 from Charleston, SC, and 22 from Greenville, SC. Patient surveys
were fully completed by 104 participants. Twenty-six genetic counselor data collection
forms were received unaccompanied by patient surveys and thus were omitted from data
analysis.
Results reported as “important” include “very important” and “somewhat
important” responses; similarly, results reported as “unimportant” include “very
unimportant” and “somewhat unimportant”. Some results are still reported as “very
important” or “very unimportant”. Non-statistically significant results can be found in
Appendix C.
2.4.1. Sample Demographics. All participants were female and pregnant. The
plurality of participants presented during their first trimester, was between the ages of 35
and 39, possessed a high school/GED education, earned between $20,000 and $50,000,
had private insurance, and received genetic counseling in Columbia, SC (Table 2.1).
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Table 2.1 Personal Characteristics of Participants
Personal
Characteristics
Location
Greenville
Charleston
Columbia
Estimated Household
Income
Less than $20,000
$20,000-$50,000
$50,000-$80,000
$80,000-$110,000
Greater than $110,000
Highest Level of Education
Less than High School
High School / GED
Associate's Degree
Bachelor's Degree
Advanced Degree
Age at Due Date
15-19
20-24
25-29
30-34
35-39
40-45
Pregnancy Trimester at Visit
First
Second
Third
Insurance
Medicaid
Private
Both

n

%

22
32
51

21%
30%
49%

31
28
12
12
17

31%
28%
12%
12%
17%

1
39
19
27
18

1%
38%
18%
26%
17%

3
4
13
12
56
16

3%
4%
13%
12%
54%
15%

58
45
1

56%
43%
1%

37
60
5

36%
59%
5%

2.4.2 Participant Indications and Prenatal Testing Offered and Selected.
Participants were referred to genetic counseling for a variety of reasons, including
advanced maternal age, a positive screening test, abnormal ultrasound findings, and a
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family history of a genetic condition. The most common indication was advanced
maternal age (Figure 2.1). This information was obtained from the genetic counselor
data collection form.
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Maternal
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First
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Trimester Findings
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Other

Figure 2.1 Participants’ Indications for Referral to Genetic Counseling
As being offered NIPT during prenatal genetic counseling was a requisite for
participation in the study, 100% of participants were offered this test.

Other possible

options included first trimester screening (FTS), chorionic villus sampling (CVS),
multiple marker screening (MMS), amniocentesis, and other (notably, one center often
wrote in “ultrasound only” for the other category). Noninvasive prenatal testing was the
test most offered to participants, with amniocentesis offered second most often. Options
for testing that were offered to participants are presented in Figure 2.2. This information
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was obtained from the genetic counselor data collection form.

Number of Participants

120

100
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Figure 2.2 Procedures Offered to Participants during Genetic Counseling
All testing options were selected at least once, with NIPT being the most common
choice (Figure 2.3). The “other” category primarily refers to participants who pursued
ultrasound only. This information was obtained from the genetic counselor data
collection form.
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Figure 2.3 Participants’ Prenatal Genetic Testing Decisions
A chi-square analysis was used to determine if participant demographic features
influenced test selection. One significant relationship was found: participants who
presented in second trimester were significantly more likely to opt not to have testing
than participants who presented in first or third trimester, 2 (2, N = 104) = 11.363, p =
.003. No significant relationship was found between participant test selection and
location, estimated household income, level of education, age at due date, or insurance.
Possible differences in uptake of NIPT based on participant indication were
evaluated. No differences were found for those studied, including: advanced maternal
age, first trimester screen positive, second trimester screen positive, abnormal ultrasound
results, family history of a genetic condition, and “other”.
A chi-square analysis was performed to look for differences in the uptake of NIPT
between participants in first, second, or third trimesters. No significant difference was
noted, 2 (2, N = 104) = 2.68, p = .262. A similar analysis was performed to look for
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differences in uptake of NIPT between the three study locations (Figure 2.4). Greenville
was noted to have the lowest uptake of NIPT, and Charleston to have the highest uptake,
but no significant differences were observed, 2 (2, N = 105) = 3.23, p = .198.
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Figure 2.4 Uptake of NIPT by Study Location
Participants were asked what other testing options they considered other than their
decision. Options included: FTS, CVS, NIPT, MMS, Amniocentesis, Other, and Not
applicable. Using chi-square analysis, a significant difference was found between
participants who chose NIPT and participants who did not in their consideration of CVS
as a prenatal test, with participants who chose NIPT more likely to have considered this
test, 2 (1, N = 95) = 4.16, p = .042. However, upon further examination with Fisher’s
Exact Test, no statistical significance was attributed to this factor (p = .054). In addition,
the factors first trimester screening, NIPT, MMS, amniocentesis, “other”, and “not
applicable” were not noted to be significant.
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2.4.3 Participant Resources used in Decision-making. In total, 73% of
participants responded “yes” to the question, “Before you saw the genetic counselor, did
you have an idea of what your decision would be?” When asked if their decision
changed during the genetic counseling session, 82% of participants responded “no”.
Participants were asked which of the following resources provided the most
information to make their decision from the following: Internet, Genetic counselor,
Family/friend, General physician, OB/GYN, Partner, Other, Not applicable. Some
participants selected more than one answer, and these were included in analysis. Most
notably, 61% of participants felt their genetic counselor provided the most information,
and 19% of participants felt their OB/GYN provided the most information. A significant
difference was not found between participants who selected NIPT and participants who
did not select NIPT for the following: internet, genetic counselor, family/friend, general
physician, OB/GYN, partner, “other”, and “not applicable”. A blank line was provided
for participants to provide a response to the “other” option, and nine participants chose to
do so. Their responses were classified into thematic groups, as follows: Healthcare
resource (n = 2), Personal beliefs/values (n = 5), and Prior experience (n = 2).
Participants were asked which resources were most helpful in making their
decision. Some participants selected more than one answer, and these were included in
analysis. In total, 68% of participants found their genetic counselor to be most helpful in
making their decision and 13% of participants found their OB/GYN to be most helpful.
No significant difference was found between participants who chose NIPT and
participants who did not for the following: internet, genetic counselor, family/friend,
general physician, OB/GYN, partner, other, not applicable. A blank line was provided for
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participants to provide a response to the “other” option, and five participants chose to do
so. Their responses were classified into thematic groups, as follows: Prior experience (n
= 1) and Personal beliefs/values (n = 4).
In general, most participants did not find test recommendations from their
OB/GYN, general physician, partner, or “someone else” to be important to their decisionmaking process. Of these options, participants most often found recommendations from
their OB/GYN to be important, with 43% designating this choice as very important or
somewhat important. No significant difference was found between participants who
selected NIPT and participants who did not select NIPT for the following: OB/GYN,
general physician, and partner.
2.4.4 Factors that Influence NIPT Decision-making. When asked to consider
the relevance to their decision of the statement, “I would consider pregnancy termination
if a chromosome condition is present,” the majority of participants (74%, n = 75) felt this
was somewhat unimportant or very unimportant. One participant (1%, n = 1) expressed
ambivalence by writing in and circling “2.5” between options “2” and “3” on a 1 through
4 Likert scale question (Figure 2.5). A chi-square analysis assessed the difference
between participants who selected NIPT and participants who did not select NIPT, and no
significant difference was noted, 2 (4, N =102) = 4.60, p = .330.
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Figure 2.5 Participants’ Response to “I would consider pregnancy termination if a
chromosome condition is present”.
The majority of participants (58%, n = 58) regarded the statement, “I would not
consider a pregnancy termination regardless of the test results” as very relevant or
somewhat relevant to their decision. One participant wrote in and circled “2.5” between
options “2” and “3” on a 1 through 4 Likert scale question (Figure 2.6). No significant
relationship was found between participants who selected NIPT and participants who did
not, 2 (4, N =100) = 3.54, p = .471.
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Figure 2.6 Participants’ Response to “I would not consider a pregnancy termination
regardless of the test results”.
A majority (91%, n = 95) of participants found the statement, “I want to be
prepared if the baby had a disability,” to be either very important or somewhat important.
A chi-square analysis was used to compare the response of participants who selected
NIPT to participants who did not select NIPT, and a significant difference was observed,

2 (3, N = 104) = 16.2, p = .001. Participants who chose NIPT were 1.3 times more likely
to feel this factor was important to their decision than participants who did not choose
NIPT. Participants who did not choose NIPT were 8.2 times more likely than
participants who chose NIPT to feel this factor was unimportant to their decision, though
it should be noted that a small sample size was represented in this category (Figure 2.7).
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Figure 2.7 Participants’ Responses to “I want to be prepared if the baby had a disability”
(1=very important, 2=somewhat important, 3=somewhat unimportant, 4=very
unimportant).
When asked to respond to the statement, “I want to avoid the risk of miscarriage
associated with some tests, the majority (88 %, n = 92) of participants felt this was very
important or somewhat important. A significant difference was not observed between
participants who selected NIPT and participants who did not when chi-square analysis
was performed, 2 (3, N = 104) = 6.51, p = .089.
A majority (81%, n = 83) of participants considered obtaining genetic information
about the fetus as early as possible in the pregnancy to be a very important or somewhat
important factor in their prenatal test decision-making. The differences between
participants who selected NIPT and those who did not were assessed and a significant
relationship was noted, 2 (3, N =103) = 11.0, p = .012, with participants who selected
NIPT 1.5 times more likely than participants who did not select NIPT to feel obtaining
genetic information about the fetus as early as possible was important. Conversely,
participants who did not select NIPT were 3.5 times more likely than participants who
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selected NIPT to feel obtaining genetic information about the fetus as early as possible
was unimportant (Figure 2.8).
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Figure 2.8 Participants’ Responses to “I want to obtain genetic information about the
fetus as early as possible” (1=very important, 2=somewhat important, 3=somewhat
unimportant, 4=very unimportant).
When asked to reflect on the statement, “I hope to learn the baby does not have
any genetic conditions”, 86% (n = 87) of participants felt it was very relevant or
somewhat relevant to their prenatal test decision. No significant difference was noted
between participants who chose NIPT and participants who did not, 2 (3, N = 101) =
5.05, p = .168.
A significant difference was observed between participants who chose NIPT and
participants who did not in their response to the statement, “I chose my decision because
this test provides more accurate information than other tests”, 2 (3, N = 102) = 9.32, p =
.025. Participants who selected NIPT were 1.4 times more likely than participants who
did not select NIPT to feel this factor was important. Conversely, participants who did
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not select NIPT were 2.5 times more likely than participants who selected NIPT to feel
this factor was unimportant (Figure 2.9). In total, 77% of participants felt this factor was
very important or somewhat important.
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Figure 2.9 Participants’ Response to “I chose my decision because this test provides more
accurate information than other tests” (1=very important, 2=somewhat important,
3=somewhat unimportant, 4=very unimportant).
Participants were asked about other test characteristics as well. When presented
the statement, “I chose my decision because this test provides results in a shorter time
span than other tests” 54% (n = 55) of total participants felt this was very relevant or
somewhat relevant to their prenatal test decision. No significant difference was found
between participants who selected NIPT and participants who did not for the turnaround
time of the test, 2 (3, N = 102) = 0.99, p = .802. When asked to rate the importance of
the statement, “The cost of the test was an important consideration,” 67% (n = 68) of
participants found the statement to be either very unimportant or somewhat unimportant.
In addition, 63% (n = 65) of participants found whether or not their insurance would pay
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for the test to be very unimportant or somewhat unimportant. No significant difference
was found between participants who selected NIPT and participants who did not for the
cost of the test, 2 (3, N = 102) = 2.61, p = .456, or insurance paying for the test, 2 (3, N
= 103) = 2.08, p = .555.
A blank line was provided for participants to provide factors they considered
important; nine participants chose to do so. Their responses were classified into thematic
groups, as follows: Concern about Down syndrome (3), Personal beliefs/values (1),
Noninvasiveness/no risk of miscarriage (2), Accuracy of test (2), Gender (1), and Prior
risk estimate (1).
In conclusion of this section, a graph was made to depict the factors that
influenced the selection of NIPT (Figure 2.10). Three factors were found to be
significantly more important to participants who selected NIPT than participants who did
not. “Other” was also found to be a significant factor, but was not included in the graph,
as responses to this factor were often unrelated to each other.
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Important for NIPT vs. not
NIPT
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Obtain Genetic
Information Early
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Figure 2.10 Factors Significantly More Important to Participants who Selected NIPT than
Participants who did Not
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Another graph was formulated to depict the top five factors of importance to total
participants in the study (Figure 2.11). Participant response is reported as total
participants (blue), participants who selected NIPT (red), and participants who did not
select NIPT (green). Factors that were significantly more important to participants who
selected NIPT than to participants who did not are designated with a white asterisk.
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Figure 2.11 Top Five Factors Most Frequently Rated as Important by Participants
2.4.5 Open-ended Response. The final question of the survey tool was an openended response question asking participants if they had any thoughts or comments about
their decision-making process that they would like to add. A total of ten participants
responded to this question; seven responses were relevant to the decision-making process
are depicted below in Table 2.2. One response is used in two thematic groups.
Table 2.2 Participant Responses to Open-response Question
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Thematic
Group

Information

Personal
Beliefs/
Values

Sub-Group

Participant Responses

Genetic
Counselor

[Genetic Counselor] made all of this so easy. Information
was explained so that we could understand everything
Grateful for having to make my own decision and grateful
for the informative information from the genetic
counselor.
I didn't know anything about a non-invasive prenatal test
until today.

I want as much information as possible just in case my
Preparation baby do have down syndrome but it will not change the
outcome.
God is in control!
Religious
In the Book of Psalm: I
This child will be loved, regardless of the ultrasound
results.
Will Not
Terminate I want as much information as possible just in case my
baby do have down syndrome but it will not change the
outcome.

2.5 Discussion
Since inclusion criteria for this study stated participants must be offered NIPT
during genetic counseling, all participants were offered this test. Incidentally, this study
consisted of a high-risk population. Indications for NIPT (and thus for participation in
this study) currently include:

advanced maternal age, an abnormal maternal serum

screen, personal or family history of aneuploidy, or an abnormal ultrasound (Wilson et
al., 2012).
However, not every testing option was offered during every genetic counseling
session. This was not secondary to the study, but a function of appropriate clinical
testing. Testing options were offered based on participant gestational age and indication.
Amniocentesis was offered during almost every session. While amniocentesis can only
be performed in second trimester, it is the most accurate diagnostic test available, so
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patients were made aware of this test whether they presented during first or second
trimester. Conversely, multiple marker screening (MMS) is less accurate than first
trimester screening (FTS) and is performed later in gestation, so MMS was not usually
discussed if patients presented in first trimester. Some tests, such as FTS and chorionic
villus sampling (CVS) can only be performed during first trimester, and as such were not
discussed if patients presented in second trimester.
Most participants indicated their genetic counselor provided the most information
and was most helpful during their decision-making process. This suggests positive
participant perception of prenatal genetic counseling and that genetic counselors played
an integral role in participant selection of prenatal testing. Interestingly, a majority
(73%) of patients had an idea of what their decision would be before genetic counseling,
and of these, most (82%) did not change their decision during the genetic counseling
session. As an overwhelming majority of participants elected to have NIPT, it seems
unlikely that such a high percentage of participants were aware of the newest test before
genetic counseling. However, it is likely they were familiar with the qualities they were
seeking in prenatal testing, and had therefore formulated an idea of what type of testing
(eg. noninvasive, screening, etc.) they would prefer, even if they were unaware of NIPT
until genetic counseling. Some participants may have heard of NIPT from their
OB/GYN. Almost half (43%) responded that a suggestion from their OB/GYN was
important to their decision, which supports similar findings by the 2011 study of pregnant
women’s interest in NIPT and physician influence by Tischler et al.
Noninvasive prenatal testing was selected over six times more frequently than any
other test. Interestingly, no difference in uptake of NIPT based on indication was noted.
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One might have expected participants with abnormal ultrasound results to be less inclined
to select NIPT, as NIPT detects aneuploidy only and is unable identify other potential
causes for ultrasound anomalies. Invasive diagnostic procedures would supply more
information about potential causes for ultrasound anomalies because testing for single
gene conditions as well as chromosomal abnormalities is available. Yet participants with
abnormal ultrasound results did not express particular interest in invasive diagnostic
testing; of seven participants with ultrasound anomalies, one selected CVS and none
selected amniocentesis.
2.5.1 Top Five Important Factors and Three NIPT-Selection Factors. The top
five factors most frequently rated as important by participants were selected for
discussion (Figure 2.11). Three factors were found to influence selection of NIPT,
meaning these factors were significantly more important to participants who selected
NIPT than to participants who did not (Figure 2.10).
The overall factor participants (91%) selected most often as important to test
selection was the desire to be prepared if the baby had a disability. This was an NIPTselection factor, as well.

In the event of a positive test result, prospective parents may

use this knowledge to prepare emotionally, make an appropriate delivery plan, and
assemble a medical management team (Benn & Chapman, 2010).
Current literature suggests women consider genetic testing to be pointless if they
would not terminate in light of a positive testing result (Reid, Sinclair, Barr, Dobbs, &
Crealey, 2009). Yet other women consider genetic testing to be empowering, even if they
would not terminate an affected pregnancy. For example, a study that surveyed parents
of children with Down syndrome found 75% were disinclined to terminate a future
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affected pregnancy, but only 33% would not have prenatal testing (Kuppermann et al.,
2011). In our study, most participants who indicated termination of an affected fetus was
irrelevant to their decision-making process opted to have prenatal genetic testing. Our
participants valued having genetic knowledge of the fetus to prepare for a possible
disability or health concern, even if they did not intend to use testing to alter the course of
their pregnancy.
Participants (81%) indicated they wanted genetic information about the fetus as
early as possible. This was both a top five factor and the most significant NIPT-selection
factor. Early detection presents many advantages for women with affected or unaffected
pregnancies. For example, early detection of unaffected pregnancies could allow for
parental reassurance and for bonding to occur sooner (Newson, 2008). As discussed
above, most participants regard a positive result as an opportunity to prepare to have a
baby with a disability.

If parents decide to terminate an affected pregnancy, the

procedure may be both physically safer and psychologically less traumatic at an earlier
gestational age (Benn & Chapman, 2010). Understandably, NIPT presents an attractive
option to participants who value obtaining genetic information about the fetus early in
gestation. With the capability of being performed as early as 10 weeks gestation, NIPT
can provide genetic information earlier than most other prenatal tests. In addition, its
availability is not restricted by a gestational time window like other prenatal testing
options (Lo, 2012).
It has been suggested that NIPT may encourage termination of affected
pregnancies without thoughtful reflection because the test provides results early in
gestation, perhaps before parents have bonded with the fetus or publicly shared the
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pregnancy (Skotko, 2009). Although participants in our study were unaware of the
genetic status of their fetus, their pre-test response did not support this speculation.
While the majority of participants who selected NIPT felt obtaining genetic information
early in gestation was important, most indicated termination of an affected fetus was
irrelevant to their decision. Furthermore, participants who selected NIPT were 1.3 times
more likely to find being prepared if the baby had a disability important than participants
who did not select NIPT.
A majority of participants (86%) indicated the desire to learn the baby did not
have any genetic conditions was important. This factor was a top five factor but was not
an NIPT-selection factor. As discussed above, patients may seek this affirmation because
a negative test result can provide reassurance and guide expectations and planning
(Newson 2008).
Many participants (77%) indicated they chose their test because it provided more
accurate information than other tests. This factor was both a top five overall factor and
an NIPT-selection factor. Of course, NIPT is not more accurate than amniocentesis or
CVS, but it is more accurate than screening tests. Thus, because this factor was
significantly important to participants who selected NIPT, we can infer its ability to
provide more accurate information than screening tests increased its uptake in our study.
A related question on the study tool asked participants which testing options they also
considered when making their decision. We wondered whether participants who selected
NIPT would more frequently consider invasive diagnostic testing (due to the increased
accuracy of the test) or screening (no associated risk of pregnancy loss). However, no
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specific test was considered significantly more often than any other by participants who
selected NIPT.
The majority of participants (88%) indicated avoiding risk of miscarriage
associated with invasive testing was important to their decision. This factor was one of
the top five factors but, surprisingly, was not an NIPT-selection factor. It has been
postulated that for many women the miscarriage risk associated with invasive testing is a
psychological barrier to diagnostic testing and that if this risk were removed, women may
feel more inclined to have a diagnostic test (Newson, 2008). To be clear, NIPT results
are not considered diagnostic, but NIPT does remove the risk of miscarriage and gives
near-diagnostic results. The majority of participants indicated learning genetic
information about the fetus was important to them; thus, it would seem participants who
wanted this information and to avoid risk of miscarriage would be motivated to pursue
NIPT. However, avoiding risk of miscarriage was not significantly more important to
participants who selected NIPT than participants who did not. We attempt to explain this
phenomenon as follows: some participants who pursued invasive diagnostic testing
indicated that ‘avoiding risk of miscarriage’ was an important factor in their decisionmaking process, even though they selected a test associated with risk of miscarriage.
This suggests that although the desire to avoid risk of miscarriage influenced their
decision, other factors were more important determinants.
This brings up an interesting point about the clinical utility of NIPT. The rapid
advancements and high sensitivity of the test has called to question whether it may be
used for diagnostic purposes. Current guidelines, however, maintain NIPT should be
considered an advanced screening test (Devers et al., 2013). Thus, a relevant role
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remains for invasive diagnostic tests. Our study indicates participants (at least some)
perceive this difference and make decisions accordingly. They recognize that NIPT,
while very advanced, does not provide as accurate nor as comprehensive information as
CVS or amniocentesis and opted to have an invasive procedure associated with risk of
miscarriage, although avoiding risk of miscarriage was important to them.

Current

literature has broached the possibility that the risk-free and simple process of NIPT will
lead to the routinization of the test, but our study suggests this was not applicable to (at
least some of our) participants’ decision making processes (Deans & Newson, 2011).
They saw value in the role of invasive diagnostic testing, despite the associated risk of
miscarriage and invasive procedure.
2.5.2 Limitations. The sample size of our study was small and representative
only of one geographic area. In general, women in South Carolina are much less likely to
terminate a pregnancy than women across the nation (Centers for Disease Control and
Prevention, 2011). This was supported by our study, as most participants indicated
avoiding termination was an important factor, but it should be noted that this population
is not representative of all women. Our survey did not address every possible factor that
could influence participant decision-making. For example, we did not ask about expected
pain related to invasive procedures or the influence of religious beliefs (although several
patients commented on the importance of their beliefs/values in the open-ended
response). Though we requested patient indication, we did not request specific risk
estimates for advanced maternal age or screen positive results. A further limitation of our
study was that we did not inquire what prenatal genetic testing participants had received
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for their current pregnancy prior to genetic counseling, and whether they had ultrasound
before or after genetic counseling.
2.5.3 Areas for Future Research. Our study surveyed pregnant women in three
cities in South Carolina about their prenatal testing decisions. Future research may use a
similar survey tool on participants in a different geographical area to observe the
difference in prenatal test decision-making. Another future study could develop a survey
to be completed by patients upon receiving NIPT results. It would be especially
interesting to record invasive diagnostic procedure uptake and termination rates for
patients with positive NIPT results.
It is predicted that NIPT may soon be offered to women with low risk pregnancies
(Norton et al., 2012). If this becomes reality, an interesting follow-up would be to repeat
this study using women of the general population, instead of women with high risk
pregnancies only. The majority of participants in the current study were of advanced
maternal age, meaning their pregnancies had increased chance for aneuploidy; however,
the majority of pregnant women in a study of the general population would not be
advanced maternal age or have this increased risk of aneuploidy. Not having this
inherent elevated risk may affect their decision-making process.
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Chapter 3. Conclusions
Patients are faced with new decisions as NIPT is integrated into prenatal testing.
This study discussed the top five factors most frequently rated as important by
participants about their prenatal testing decision and identified three NIPT-selection
factors. Participants tended to want testing to be prepared if the baby had a disability, to
avoid the risk of miscarriage, to be reassured the baby was unaffected, to obtain fetal
genetic information as early as possible, and to have a test that provides more accurate
results than other tests. Participants who selected NIPT were significantly more likely to
want to obtain fetal genetic information as early as possible, to have a test that provides
more accurate information than other tests, and to be prepared if the baby had a disability.
While every patient should be counseled as a unique individual, the results from this
study are observations that may help healthcare providers better understand patient
perspective. This study reveals five factors important to patient decision-making
regarding prenatal testing; of these, three factors (obtaining genetic information about the
fetus as early as possible, having a test that provides more accurate information than
other tests, and being prepared if the baby had a disability) were significantly influential
in patient selection of NIPT.
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Appendices
Appendix A: Patient Survey
Dear patient,
Thank you for your interest in our research study. The purpose of our research is to
examine how women make decisions regarding prenatal testing. This survey should take
about 10 minutes to complete, and it may be returned to your genetic counselor or mailed
in the return envelope provided. Any questions or concerns regarding this research may
be directed to Kim Hamann, principle investigator, at (859) 803-3437 or Janice Edwards,
project advisor, at (803) 545-5706. Questions about rights as a research participant may
be directed to the Office of Research Compliance at the University of South Carolina at
(803) 777-7095 or the Office of Research Integrity at the Medical University of South
Carolina at (843) 792-4148.
Participation is voluntary and confidential. You may skip any questions you do not want
to answer. Your genetic counselor will complete a short data collection form about your
testing options and preferences.
The questions in this survey often reference “your decision”. You might have decided:
 To have a specific prenatal test
 Not to have more prenatal testing
 Or, you might not have decided yet
Whatever choice you make is the right one for you and your genetic counselor supports
your decision. Please reflect on your decision-making process in the following questions:

Reflecting on your decision…
1. Before you saw the genetic counselor, did you have an idea of what your decision
would be?
a. Yes
b. No (If you answer no to Question #1, please skip to question #3.)
2. Did your decision change during genetic counseling?
a. Yes
b. No
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3. Which resource provided the most information to make your decision?
a. Internet
b. Genetic counselor
c. Family/friend
d. General physician
e. OB/GYN
f. Partner
g. Other____________________________________________________
h. Not applicable
4. Which resource was most helpful in making your decision?
a. Internet
b. Genetic counselor
c. Family/friend
d. General physician
e. OB/GYN
f. Partner
g. Other__________________________________________________
h. Not applicable
5. When you were making your decision, did you consider any other options? If so,
please circle all that apply.
a. First trimester screening
b. CVS
c. Non-invasive prenatal testing
d. Multiple marker screening
e. Amniocentesis
f. Other _________________________________
g. Not applicable
Considering your decision-making process…
Please consider the following statements and rate their importance to your decision as
you were presented different testing options, where 1 is very important and 4 is very
unimportant:
Very important
1

2

3

Very unimportant
4

6. Whether or not my insurance company would pay for the test was an important
consideration
1
2
3
4
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7. The cost of the test was an important consideration
1
2
3
4
8. I want to obtain test results before I tell others I am pregnant
1
2
3
4
9. I wish to know nothing about the genetic makeup of the baby
1
2
3
4
10. I want to be prepared if the baby had a disability
1
2
3
4
11. I want to avoid the risk of miscarriage associated with some tests
1
2
3
4
12. I want to obtain genetic information about the pregnancy as early as possible
1
2
3
4
13. Other factors that were important to your decision may be listed below
__________________________________________________________________
1
2
3
4

Please consider the following statements and rate their relevance to your decision as you
were presented different testing options, where 1 is very relevant and 4 is very irrelevant:
Very relevant
1

2

3

Very irrelevant
4

14. I had a positive screening test and am concerned that a chromosome condition
may be present
1
2
3
4
15. I would consider pregnancy termination if a chromosome condition is present
1
2
3
4
16. I chose my decision because this test provides more accurate information than
other tests
1
2
3
4
17. I chose my decision because this test provides results in a shorter time span than
other tests
1
2
3
4
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18. My OB/GYN suggested this decision, which heavily influenced my decision
1
2
3
4
19. My general physician suggested this decision, which heavily influenced my
decision
1
2
3
4
20. My partner suggested this decision, which heavily influenced my decision
1
2
3
4
21. Someone else suggested this decision, which heavily influenced my decision
1
2
3
4
22. I would not consider pregnancy termination regardless of test results
1
2
3
4
23. I hope to learn the baby does not have any genetic conditions
1
2
3
4
24. Other____________________________________________________________
1
2
3
4
A couple more questions about you…
1. How old will you be at the expected due date? ________________
2. How many weeks pregnant are you? ______________________
3. Please list your insurance provider. _______________________
4. Please estimate your annual household income
a. Below $20,000
b. $20,000-$50,000
c. $50,000-$80,000
d. $80,000-$110,000
e. Above $110,000
5. What is your highest completed level of education?
a. Less than high school
b. High school/GED
c. Associate’s degree
d. Master’s degree
e. Advanced degree
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A Final Question
If there are any thoughts or comments about your decision-making process that you
would like to add, please do so in the space below:
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Appendix B: Genetic Counselor Data Collection Form
Please answer the following in regards to your patient…
1. Which of the following indications prompted the patient’s visit to genetic
counseling? (Circle all that apply.)
a. Maternal age greater than 35
b. First trimester screening was positive for trisomy 21, 18, or 13
c. Second trimester screening was positive for trisomy 21 or 18
d. Abnormal ultrasound findings
e. Family history of
_________________________________________________
f. Other
__________________________________________________________
2. The gestational age of the patient was ________ weeks at the time of genetic
counseling.
3. Which of the following procedures was offered to the patient during this session?
(Circle all that apply.)
a. First trimester screening
b. CVS
c. Non-invasive prenatal testing
d. Multiple marker screening
e. Amniocentesis
f. Other
___________________________________________________________
4. Which of the following has the patient chosen at this time? Only select the
method she is currently pursuing. (Do not select a screening test if she has
already had one for this pregnancy.)
a. First trimester screening
b. CVS
c. Non-invasive prenatal testing
d. Multiple marker screening
e. Amniocentesis
f. Has decided not to pursue any testing
g. Has not decided
h. Other __________________________________

67

Appendix C: Statistical Analysis Results
Table C.1 Factors Influencing NIPT Selection
χ2

df

n

p-value

0.868

1

105

0.351

0.837

1

105

0.360

0.072

1

105

0.788

1

105

0.954

0.041

1

105

0.840

1.31

1

104

0.252

χ

df

n

p-value

0.076

1

95

0.783

4.16
0.022
2.68
2.99
0.040
0.455

1
1
1
1
1
1

95
95
95
95
95
95

0.042
0.883
0.102
0.084
0.841
0.500

Most Information
Internet
Genetic Counselor
Family/Friend
General Physician
OB/GYN
Partner
Other
Not Applicable

χ2
0.207
0.660
0.119
0.441
0.016
1.16
0.026
0.013

df
1
1
1
1
1
1
1
1

n
102
102
102
102
102
102
102
102

p-value
0.649
0.416
0.730
0.507
0.901
0.282
0.872
0.910

Most Helpful
Internet
Genetic Counselor
Family/Friend
General Physician
OB/GYN
Partner
Other

χ2
0.030
0.050
0.062
0.409
0.669
0.007
0.030

df
1
1
1
1
1
1
1

n
102
102
102
102
102
102
102

p-value
0.863
0.823
0.803
0.552
0.413
0.932
0.863

Indication
Advanced Maternal
Age
Positive First
Trimester Screen
Positive Second
Trimester Screen
Abnormal Ultrasound
Results
Family History of
Genetic Condition
Other
Testing Options
First Trimester
Screening
CVS
NIPT
MMS
Aminocentesis
Other
Not Applicable

0.003

2
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Not Applicable

2.46

1

102

0.117

Demographics
Location
Estimated Annual
Household Income
Level of Education
Trimester
Age at Due Date
Insurance

χ2
3.239

df
2

n
105

p-value
0.198

8.551

4

100

0.073

2.167
2.682
35.767
3.476

4
2
36
2

104
104
102
77

0.705
0.262
0.480
0.176

Suggested Decision
OB/GYN
General Physician
Partner
Someone Else

χ2
2.319
2.247
2.306
1.937

df
3
3
3
3

n
100
95
98
99

p-value
0.509
0.523
0.511
0.586

Table C.2 Demographic Features Influencing Participant Decisions Not to have Testing
No Testing
2
Demographics
χ
df
n
p-value
Trimester
11.363
2
104
0.003
Age at Due Date
17.474
25
104
0.864
Insurance
0.449
2
102
0.799
Estimated Annual
3.086
4
100
0.544
Household Income
Level of Education
0.959
4
104
0.916
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